2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - Great Hall BC
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Artificial Intelligence (AI), Machine Learning, Biological Processes, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, APL, Translational Research, Clinical Research, Real-World Evidence, Study Population, Human, Adult
PAPER

503 Clinical and molecular landscape of CSF3R-mutated acute myeloid leukemia: Insights from a multicenter cohort including the Harmony Platform

Lara Hövel, MD, Angela Villaverde Ramiro2, Rabea Mecklenbrauck, MD3, Razif Gabdoulline4, Henri C. Hupe, MD5, Wencke Walter, PhD6, Brian Huntly, MD7, Ian F. Thomas8, Klaus H Metzeler, MD9, Christian Thiede, Prof.10, Christoph Röllig, MD11, Guadalupe Oñate Sr12, Jorge Sierra, MD, PhD13, Peter JM Valk, PhD14, Jurjen Versluis Sr, MD, PhD15, Ken Ian Mills, Prof16, Amin T. Turki, MD, PhD17, Walter Fiedler, MD18, Franziska Westendorf, MD19, Konstanze Döhner, MD20, Arnold Ganser I, MD21, Florian H. Heidel IV, MD22, Michael Heuser, MD23, Torsten Haferlach, MD, PhD24, Lars Bullinger, Prof. Dr. med.25, Felicitas R Thol, MD26
1 Hannover Medical School, Hannover, Germany
2 Cancer Research Center of Salamanca (USAL-CSIC), Salamanca, Spain, HARMONY Alliance Foundation, Salamanca, Spain, Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain
3 Hannover Medical School, Hannover, Germany, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
4 Hannover Medical School, Hannover, Germany
5 Hannover Medical School, Hannover, Germany
6 MLL Munich Leukemia Laboratory, Munich, Germany
7 Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom
8 Centre for Trials Research, School of Medicine, Cardiff University, Cardiff, United Kingdom
9 Leipzig University Medical Center, Leipzig, Germany
10 University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany
11 University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany
12 Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain
13 Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain
14 Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands
15 Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands
16 Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, United Kingdom
17 Computational Hematology Lab, Institute for AI in Medicine, University Hospital Essen, Essen, Germany
18 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
19 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
20 University Hospital Ulm, Ulm, Germany
21 Hannover Medical School, Hannover, Germany
22 Hannover Medical School, Hannover, Germany
23 Hannover Medical School, Hannover, Germany, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle, Germany
24 MLL Munich Leukemia Laboratory, Munich, Germany
25 Charité – Universitätsmedizin Berlin, Berlin, Germany
26 Hannover Medical School, Hannover, Germany

Background

CSF3R mutations are established drivers of chronic neutrophilic leukemia (CNL) but are rare and incompletely characterized in acute myeloid leukemia (AML). Previous studies comprised small cohorts, limiting conclusions regarding their clinical relevance and prognostic implications. We therefore investigated the clinical characteristics, molecular landscape, and outcomes of CSF3R-mutated AML in a large multicenter cohort.

Methods

Adult patients with AML harboring pathogenic or likely pathogenic CSF3R mutations were identified across cohorts from Hannover Medical School, the HARMONY Platform, and the Munich Leukemia Laboratory. Patients with acute promyelocytic leukemia or AML following severe congenital neutropenia were excluded. Molecular characteristics and survival outcomes were compared with those of an external CSF3R-wild-type (wt) AML cohort. Overall survival (OS) and event-free survival (EFS) were analyzed in intensively treated patients using Kaplan-Meier and Cox regression.

Results

Among 15,284 patients with available CSF3R information, 205 harbored CSF3R mutations (1.34%). Of 201 evaluable variants, 77.1% localized to the cytoplasmic domain and 22.9% to the membrane-proximal region, with activating variants predominating in the membrane-proximal region (84.8%) and truncating variants accounting for 60.0% of cytoplasmic alterations. Truncating mutations was the most frequent functional class overall (46.3%), while T618I was the most common individual variant (24.4%). Median CSF3R variant allele frequency was 22.2% (range, 1.1–95.7%) and CSF3R represented the dominant clone in 18.9% of patients. Age and sex distribution were comparable between CSF3R-mutated and CSF3R-wt patients (56.0 vs 62.2 years, p=0.30; female, 48.8% vs 40.7%, p=0.051). Secondary AML was more common in CSF3R-mutated than CSF3R-wt patients (42.9% vs 14.4%, p<0.001), as was ELN2022 adverse-risk disease (62.0% vs 33.0%, p<0.001). CSF3R-mutated patients had lower white blood cell counts (median, 10.0 vs 21.2 ×10⁹/L, p<0.001) and hemoglobin levels (8.6 vs 9.3 g/dL, p=0.032), whereas platelet counts (51 vs 56 ×10⁹/L, p=0.80) and the frequency of complex karyotypes (7.6% vs 8.4%, p=0.20) were comparable. CSF3R-mutated AML was enriched for t(8;21) (14.1% vs 5.0%, p<0.001), whereas normal karyotypes were less frequent (37.5% vs 55.8%, adjusted p<0.001). CSF3R-mutated AML showed a distinct co-mutational profile, most frequently involving RUNX1 (34.3%), ASXL1 (22.5%), DNMT3A (20.0%), and TET2 (19.5%). Compared with CSF3R-wt AML, mutations affecting RUNX1, ASXL1, EZH2, RAD21, BCOR, CEBPA, ASXL2, GATA2, ZRSR2, and NF1 were enriched, whereas NPM1 and FLT3 mutations were less common (all p<0.001).

Among intensively treated patients, the complete remission rate was 80.4% (82/102). Median OS was longer in CSF3R-mutated than CSF3R-wt patients (65.3 vs 17.1 months, p<0.001), whereas EFS did not differ significantly (11.7 vs 16.5 months, p=0.50). OS did not differ within the ELN2022 favorable- or intermediate-risk groups. In adverse-risk AML, CSF3R-mutated patients had longer OS than CSF3R-wt patients (19.5 vs 10.0 months, HR 0.43, p<0.001). This association remained significant after adjustment for age and white blood cell count (HR 0.54, p=0.0039), but was attenuated after additional adjustment for allogeneic hematopoietic cell transplantation (HR 0.70, p=0.12). In an exploratory subgroup analysis, CSF3R-mutated patients with RUNX1 mutations showed longer OS than their CSF3R-wt counterparts (n=28 vs n=84; HR 0.35, p<0.001). This association remained significant after adjustment for age, white blood cell count, ELN2022 risk, and AML type (HR 0.49, p=0.038). There was no evidence of significant OS differences according to CSF3R status in core-binding factor AML (n=26 vs n=61, p=0.77) or CEBPA double-mutated AML (n=4 vs n=8, p=0.29), although subgroup sizes were small.

Conclusion

CSF3R-mutated AML defines a rare molecular subgroup with a heterogeneous variant architecture that differs from the hotspot-dominated mutation spectrum of CNL. It is further characterized by predominantly myelodysplasia-related clinical and molecular characteristics, including frequent secondary disease, adverse-risk classification, and enrichment of transcription factor and epigenetic/chromatin regulator mutations. High remission rates were not accompanied by improved EFS, and observed OS differences varied according to clinical and molecular context.

Lara Hövel, MD: No relevant conflicts of interest to declare.